Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...
Orsini has been chosen by Vertex Pharmaceuticals Incorporated to dispense gene-editing therapy CASGEVY® (exagamglogene ...
It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.
With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an ...
Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.
A Feature analyzing M&A, licensing and partnerships in gene editing as CRISPR therapeutics enter the market and present new ...
Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...
Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at ...
BTIG analyst Mark Massaro reiterated a Buy rating on MaxCyte (MXCT – Research Report) yesterday and set a price target of $8.00. Mark ...
MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, ...